These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17683075)

  • 1. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer.
    Levin AM; Zuhlke KA; Ray AM; Cooney KA; Douglas JA
    Prostate; 2007 Oct; 67(14):1507-13. PubMed ID: 17683075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population.
    FitzGerald LM; Thomson R; Polanowski A; Patterson B; McKay JD; Stankovich J; Dickinson JL
    Prostate; 2008 Sep; 68(13):1373-9. PubMed ID: 18537123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
    Zheng SL; Chang BL; Faith DA; Johnson JR; Isaacs SD; Hawkins GA; Turner A; Wiley KE; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
    Cancer Res; 2002 Nov; 62(22):6485-8. PubMed ID: 12438241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
    Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ
    Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
    Rubin MA; Bismar TA; Andrén O; Mucci L; Kim R; Shen R; Ghosh D; Wei JT; Chinnaiyan AM; Adami HO; Kantoff PW; Johansson JE
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1424-32. PubMed ID: 15941951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer.
    Daugherty SE; Shugart YY; Platz EA; Fallin MD; Isaacs WB; Pfeiffer RM; Welch R; Huang WY; Reding D; Hayes RB
    Prostate; 2007 Oct; 67(14):1487-97. PubMed ID: 17680641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
    Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
    Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
    Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
    Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
    Ananthanarayanan V; Deaton RJ; Yang XJ; Pins MR; Gann PH
    Prostate; 2005 Jun; 63(4):341-6. PubMed ID: 15602744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
    Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
    Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
    Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
    J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
    Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
    Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
    Zha S; Isaacs WB
    Mol Cancer Res; 2005 Feb; 3(2):110-8. PubMed ID: 15755877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of incorporating genetic variants for the early detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
    Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology.
    Shen-Ong GL; Feng Y; Troyer DA
    Cancer Res; 2003 Jun; 63(12):3296-301. PubMed ID: 12810662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer.
    Mubiru JN; Valente AJ; Troyer DA
    Prostate; 2005 Oct; 65(2):117-23. PubMed ID: 15880524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
    Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of MUC1 genetic variation on prostate cancer risk and survival.
    Strawbridge RJ; Nister M; Brismar K; Li C; Lindström S
    Eur J Hum Genet; 2008 Dec; 16(12):1521-5. PubMed ID: 18628787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.